US approves sickle cell breakthrough with gene editing therapy

The United States on Friday approved the first medicine to use gene editing tool CRISPR in a breakthrough for treatment of sickle cell disease, a debilitating inherited blood disorder.

The US Food and Drug Administration said it had “approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease.”